CRF awards four global grants to advance CHM research toward new clinical trial endpoints and therapeutic approaches—driving progress toward treatments.

The MarketWatch News Department was not involved in the creation of this content.-- Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which ...

Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. | Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug ...

Raised blood pressure remains the leading modifiable risk factor for cardiovascular disease and premature mortality worldwide ...

A new study has uncovered how an exceptionally scarce protein can orchestrate the assembly of large-scale gene-silencing structures inside cells, and what happens when that process breaks down. The ...

Dr. Todd Maderis, ND  Exploring immune dysregulation, viral reactivation, mitochondrial impairment, and treatment implications in post-EBV fatigue syndromes ...

Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings ...

Lockheed secured a $1.9 billion Air Force contract to produce and support C-130J training systems under the JMATS IV program ...

Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage oncology biotechnology company, today announced its official launch following a period of stealth operations. The ...

Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive ...

Below, we’ve brought together the month’s themes in our new Trends Outside the Headlines, trends & insights report, collecting together and assessing the signals that matter for life sciences ...

In modern information technology, the efficient and dynamic manipulation of these light "codes" is key to achieving ...